U.S. FDA panel backs Pfizer’s low-dose COVID-19 vaccine for children

A Food and Drug Administration advisory panel voted unanimously, that the vaccine’s benefits in preventing COVID-19 in the 5-11 age group outweigh any potential risks.

from The Hindu - International https://ift.tt/3vRgHSL